Ascletis Partners with Simcere for Ritonavir Supply in COVID-19 Drug Development
China-based Ascletis Pharma Inc. (HKG: 1672) has announced that its wholly-owned subsidiary Ascletis Pharmaceuticals Co.,...
COVID-19
Simcere’s COVID-19 Drug SIM0417 Accepted for Special Review by NMPA
China-based Simcere Pharmaceutical Group (HKG: 2096) has announced that the National Medical Products Administration (NMPA)...
Ascletis Pharma Initiates Dosing in Phase I Trial for COVID-19 Treatment ASC11
China-based Ascletis Pharma Inc. (HKG: 1672) has announced the dosing of four healthy subjects in...
Clover Biopharmaceuticals Plans COVID-19 Vaccine SCB-2019 Launch in China for 2023
China-based Clover Biopharmaceuticals, Ltd (HKG: 2197) has provided updates on its plans for the commercialization...
Meheco’s Genertec Partners with AstraZeneca for COVID-19 Antibody Evusheld in China
China Meheco Group Co., Ltd (SHA: 600056) announced that its subsidiary Genertec Meheco has entered...
MSD China to Take Legal Action Against Market Infringement of Molnupiravir
Merck Sharp & Dohme (MSD, NYSE: MRK)’s China unit has issued a WeChat notification vowing...
Meihua Partners with Getein Biotech to Manufacture COVID-19 Antigen Tests
China-based Meihua International Medical Technologies Co., Ltd (NASDAQ: MHUA) has announced a strategic partnership with...
MSD Submits Initial Quotation for Molnupiravir in China Amid New COVID-19 Rules
Under new rules specifically for the launch of COVID-19 therapeutics in China, US-based Merck Sharp...
CanSino Biologics to Issue GDRs on SWX Swiss Exchange to Boost Globalization
China-based CanSino Biologics (SHA: 688185, HKG: 6185) has announced plans to issue an undisclosed amount...
Cosunter’s COVID-19 Drug GST-HG171 Shows Superior Efficacy in Trial
China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced positive results from an investigator-initiated...
Fosun Foundation Donates COVID-19 Therapy Azvudine to Rural China
The Fosun Foundation, Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), and Henan...
NMPA Approves Expanded Production for COVID-19 Symptom Treatments
The National Medical Products Administration (NMPA) has approved filings from multiple companies to expand manufacturing...
China Optimizes Medical Insurance Policies for COVID-19 Treatment
The National Healthcare Security Administration (NHSA), Ministry of Finance, National Health Commission, and Chinese Center...
Pfizer’s Paxlovid Excluded from China’s NRDL Amid Price Dispute
The National Reimbursement Drug List (NRDL) negotiations have concluded, with Pfizer’s (NYSE: PFE) COVID-19 therapy...
China’s National Health Commission Releases Updated COVID-19 Treatment Plan
The National Health Commission (NHC) has released the 10th edition of the national COVID-19 Diagnosis...
HutchMed’s Sovleplenib Administered to First Patient in Phase II COVID-19 Study
On January 4, Hutchison China Meditech (HutchMed; HKG: 0013, NASDAQ: HCM) administered its novel, investigational,...
Salubris Pharmaceuticals Gains NMPA Approval for Phase I Study of SAL0133
China’s Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) has announced receiving approval from the National...
CanSino Biologics’ mRNA Vaccine CS-2034 Shows Positive Safety and Immunogenicity Data
China-based CanSino Biologics (HKG: 6185) has announced positive periodical data from a clinical study assessing...
NMPA Strengthens Oversight of COVID-19 Drugs and Home Treatment Guidelines
The National Medical Products Administration (NMPA) has released a notification aimed at enhancing the quality...
NMPA Approves Chinabridge’s ECMO Equipment for Emergency Use
The National Medical Products Administration (NMPA) has approved Chinabridge (Shenzhen) Medical Technology Co., Ltd’s extracorporeal...